Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimimazolam tosilate for prevention of postoperative cognitive dysfunction after knee surgery
ChiCTR2100046613Phase 4Recruiting
- Sponsor
- Zunyi Medical University Affiliated Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in post-operative cognitive decline (POCD) (4 arms), sponsored by Zunyi Medical University Affiliated Hospital. Primary endpoint: Incidence of postoperative cognitive dysfunction. Started Sep 2021; status: recruiting.
02
Drugs
remimazolam
03
Conditions
post-operative cognitive decline (POCD)
Beyond the preview
Go deeper on ChiCTR2100046613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046613.